Neuron23

Executive Summary

Neuron23 is a clinical-stage biotechnology company based in South San Francisco, California, that leverages advanced data science, human genetics, and machine learning to develop precision medicines for genetically defined neurological and immunological diseases. The company's lead program targets Parkinson's disease, with a focus on addressing underlying disease drivers rather than just symptoms. By integrating AI/ML with human genetics, Neuron23 aims to identify and validate novel drug targets and biomarkers, enabling a patient-centric approach to therapy development. The company is currently in Phase 2 clinical development and has demonstrated an ability to move from discovery to clinical proof-of-concept efficiently. With a strong scientific foundation and a clear precision medicine strategy, Neuron23 is positioned to address significant unmet needs in neurology and immunology, areas where genetic insights are increasingly guiding therapeutic intervention. The company's progress to date and its focus on genetically defined patient populations reduce development risk and increase the likelihood of regulatory success.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead Parkinson's disease candidate60% success
• Q1 2027Initiation of Phase 1/2 trial for next-generation neurology asset70% success
• Q4 2026Presentation of preclinical data for immunology pipeline candidate80% success